NASDAQ:PCRX - Pacira Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $38.22 -1.53 (-3.85 %) (As of 03/25/2019 08:43 AM ET)Previous Close$39.75Today's Range$38.22 - $39.8552-Week Range$26.95 - $55.00Volume271,705 shsAverage Volume659,935 shsMarket Capitalization$1.58 billionP/E Ratio131.79Dividend YieldN/ABeta1.49 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a partnership with Thermo Fisher Scientific Pharma Services for the commercial production of EXPAREL. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey. Receive PCRX News and Ratings via Email Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:PCRX Previous Symbol CUSIP69512710 CIK1396814 Webwww.pacira.com Phone973-254-3560Debt Debt-to-Equity Ratio0.90 Current Ratio7.88 Quick Ratio7.08Price-To-Earnings Trailing P/E Ratio131.79 Forward P/E Ratio57.04 P/E Growth2.38 Sales & Book Value Annual Sales$337.28 million Price / Sales4.67 Cash Flow$0.9560 per share Price / Cash Flow39.98 Book Value$7.81 per share Price / Book4.89Profitability EPS (Most Recent Fiscal Year)$0.29 Net Income$-470,000.00 Net Margins-0.14% Return on Equity3.94% Return on Assets1.80%Miscellaneous Employees518 Outstanding Shares41,230,000Market Cap$1.58 billion Next Earnings Date5/2/2019 (Estimated) OptionableOptionable Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions What is Pacira Pharmaceuticals' stock symbol? Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX." How were Pacira Pharmaceuticals' earnings last quarter? Pacira Pharmaceuticals Inc (NASDAQ:PCRX) announced its earnings results on Thursday, February, 28th. The company reported $0.28 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.07 by $0.21. The business earned $95.12 million during the quarter, compared to analysts' expectations of $93.69 million. Pacira Pharmaceuticals had a positive return on equity of 3.94% and a negative net margin of 0.14%. The company's quarterly revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the business posted $0.38 earnings per share. View Pacira Pharmaceuticals' Earnings History. When is Pacira Pharmaceuticals' next earnings date? Pacira Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 2nd 2019. View Earnings Estimates for Pacira Pharmaceuticals. What price target have analysts set for PCRX? 18 brokerages have issued twelve-month price objectives for Pacira Pharmaceuticals' stock. Their forecasts range from $33.00 to $85.00. On average, they expect Pacira Pharmaceuticals' share price to reach $54.0667 in the next year. This suggests a possible upside of 41.5% from the stock's current price. View Analyst Price Targets for Pacira Pharmaceuticals. What is the consensus analysts' recommendation for Pacira Pharmaceuticals? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Pharmaceuticals in the last year. There are currently 3 sell ratings, 6 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacira Pharmaceuticals. What are Wall Street analysts saying about Pacira Pharmaceuticals stock? Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock: 1. According to Zacks Investment Research, "Pacira's top line mainly comprises contribution from its marketed product Exparel. The company’s efforts to expand Exparel's label are encouraging. In April 2018, the FDA approved Exparel's label expansion to include administration via nerve block for prolonged regional analgesia. This is a positive for the company as it will further boost sales of Exparel. Pacira remains optimistic about its partnership with J&J to market and promote the use of Exparel with respective sales and medical education teams. Pacira’s agreement with China-based Nuance for the development and commercialization of Exparel in China is also an upside. Shares of Pacira have outperformed the industry in 2018. However, the company remains heavily dependent on Exparel for growth, which is concerning." (1/3/2019) 2. Mizuho analysts commented, "We valued Pacira based on an equally weighted blend of discounted cash flow analysis and sum-of-the-parts valuation. This analysis generates our $43 price target, supporting our Neutral rating." (11/1/2018) 3. HC Wainwright analysts commented, "Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back)." (7/10/2018) Has Pacira Pharmaceuticals been receiving favorable news coverage? News stories about PCRX stock have been trending somewhat negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pacira Pharmaceuticals earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Who are some of Pacira Pharmaceuticals' key competitors? Some companies that are related to Pacira Pharmaceuticals include Marina Biotech (MRNA), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND), Array Biopharma (ARRY), Horizon Pharma (HZNP), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), Amneal Pharmaceuticals (AMRX) and TESARO (TSRO). What other stocks do shareholders of Pacira Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Pharmaceuticals investors own include Gilead Sciences (GILD), Celgene (CELG), Clovis Oncology (CLVS), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Ionis Pharmaceuticals (IONS), Netflix (NFLX), Nektar Therapeutics (NKTR) and Sangamo Therapeutics (sgmo). Who are Pacira Pharmaceuticals' key executives? Pacira Pharmaceuticals' management team includes the folowing people: Mr. David M. Stack, Chairman & CEO (Age 69)Mr. Charles A. Reinhart III, C.P.A., M.B.A., Chief Financial Officer (Age 58)Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 57)Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 40) Who are Pacira Pharmaceuticals' major shareholders? Pacira Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Macquarie Group Ltd. (5.20%), Millennium Management LLC (2.98%), Baillie Gifford & Co. (2.27%), Polar Capital LLP (1.46%), Elk Creek Partners LLC (1.30%) and Partner Fund Management L.P. (1.27%). Company insiders that own Pacira Pharmaceuticals stock include Andreas Wicki, Charles A Reinhart III, David M Stack, Gary W Pace, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals. Which institutional investors are selling Pacira Pharmaceuticals stock? PCRX stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Bank of New York Mellon Corp, Macquarie Group Ltd., Millennium Management LLC, Elk Creek Partners LLC, Castleark Management LLC, Canada Pension Plan Investment Board and United Services Automobile Association. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Andreas Wicki, Charles A Reinhart III, David M Stack, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals. Which institutional investors are buying Pacira Pharmaceuticals stock? PCRX stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Polar Capital LLP, D. E. Shaw & Co. Inc., Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Baillie Gifford & Co., Two Sigma Advisers LP and Two Sigma Investments LP. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Gary W Pace, Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals. How do I buy shares of Pacira Pharmaceuticals? Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Pacira Pharmaceuticals' stock price today? One share of PCRX stock can currently be purchased for approximately $38.22. How big of a company is Pacira Pharmaceuticals? Pacira Pharmaceuticals has a market capitalization of $1.58 billion and generates $337.28 million in revenue each year. The company earns $-470,000.00 in net income (profit) each year or $0.29 on an earnings per share basis. Pacira Pharmaceuticals employs 518 workers across the globe. What is Pacira Pharmaceuticals' official website? The official website for Pacira Pharmaceuticals is http://www.pacira.com. How can I contact Pacira Pharmaceuticals? Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected] MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 645 (Vote Outperform)Underperform Votes: 454 (Vote Underperform)Total Votes: 1,099MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: What is a blue-chip stock?